Abstract
The senescence accelerate mouse P8 (SAMP8) is an excellent model of early learning and memory problems. A number of studies have shown that it has cholinergic deficits, oxidative damage, alterations in membrane lipids and circadian rhythm disturbances. The brains of the SAMP8 overproduce amyloid precursor protein (APP), amyloid-beta protein and have an increased physphorylation of tau. An antisense to APP has been developed that reverses the cognitive deficits and oxidative damage. This antisense represents a poten-tial treatment for Alzheimers disease.
Keywords: Antisense, amyloid-beta, SAMP8, oxidative damage, Alzheimer's, blood brain barrier, testosterone, amyloid precursor protein (APP), cognitive deficits
Current Pharmaceutical Design
Title: The SAMP8 Mouse: A Model to Develop Therapeutic Interventions for Alzheimers Disease
Volume: 18 Issue: 8
Author(s): John E. Morley, Susan A. Farr, Vijaya B. Kumar and Harvey J. Armbrecht
Affiliation:
Keywords: Antisense, amyloid-beta, SAMP8, oxidative damage, Alzheimer's, blood brain barrier, testosterone, amyloid precursor protein (APP), cognitive deficits
Abstract: The senescence accelerate mouse P8 (SAMP8) is an excellent model of early learning and memory problems. A number of studies have shown that it has cholinergic deficits, oxidative damage, alterations in membrane lipids and circadian rhythm disturbances. The brains of the SAMP8 overproduce amyloid precursor protein (APP), amyloid-beta protein and have an increased physphorylation of tau. An antisense to APP has been developed that reverses the cognitive deficits and oxidative damage. This antisense represents a poten-tial treatment for Alzheimers disease.
Export Options
About this article
Cite this article as:
E. Morley John, A. Farr Susan, B. Kumar Vijaya and J. Armbrecht Harvey, The SAMP8 Mouse: A Model to Develop Therapeutic Interventions for Alzheimers Disease, Current Pharmaceutical Design 2012; 18 (8) . https://dx.doi.org/10.2174/138161212799315795
DOI https://dx.doi.org/10.2174/138161212799315795 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Towards Improved Acetylcholinesterase Inhibitors: A Structural and Computational Approach
Mini-Reviews in Medicinal Chemistry Sirtuins: Developing Innovative Treatments for Aged-Related Memory Loss and Alzheimer’s Disease
Current Neurovascular Research Kawasaki Disease and Its Treatment – An Update
Current Rheumatology Reviews Blockade of Renin Angiotensin System in Heart Failure Post-Myocardial Infarction: What is the Best Therapy?
Recent Patents on Cardiovascular Drug Discovery Metformin: A Growing Journey from Glycemic Control to the Treatment of Alzheimer’s Disease and Depression
Current Medicinal Chemistry Ginkgo biloba Extract 761: A Review of Basic Studies and Potential Clinical Use in Psychiatric Disorders
CNS & Neurological Disorders - Drug Targets Mitochondrial Metabolism Modulation: A New Therapeutic Approach for Parkinsons Disease
CNS & Neurological Disorders - Drug Targets BACE1 Levels Correlate with Phospho-Tau Levels in Human Cerebrospinal Fluid
Current Alzheimer Research Editorial [Hot topic: Transgenic Animal Models of Neurodegenerative Diseases (Guest Editor: Stephen D. Skaper)]
CNS & Neurological Disorders - Drug Targets Recent Studies on Design and Development of Drugs Against Alzheimer’s Disease (AD) Based on Inhibition of BACE-1 and Other AD-causative Agents
Current Topics in Medicinal Chemistry The NGF Metabolic Pathway in the CNS and its Dysregulation in Down Syndrome and Alzheimer’s Disease
Current Alzheimer Research Atherogenic Versus Non-atherogenic Lipoprotein Profiles in Healthy Individuals. Is There a Need to Change Our Approach to Diagnosing Dyslipidemia?
Current Medicinal Chemistry A Protective Role of Translocator Protein in Alzheimer’s Disease Brain
Current Alzheimer Research Preface [Hot Topic: Amyloidogenic Proteins and Peptides Involved in Human Neurodegenerative Diseases (Guest Editor: Brian m. Austen)]
Protein & Peptide Letters Editorial - Progress of Current Alzheimer Research
Current Alzheimer Research Usefulness of 18F Florbetaben in Diagnosis of Alzheimer’s Disease and Other Types of Dementia
Current Alzheimer Research Neuronal Ceroid Lipofuscinosis: The Increasing Spectrum of an Old Disease
Current Molecular Medicine The Role of Microbial Agents in the Etiology of Schizophrenia: An Infectious Hypothesis for Psychosis?
Current Immunology Reviews (Discontinued) The Efficacy of Cognitive Intervention Programs for Mild Cognitive Impairment: A Systematic Review
Current Alzheimer Research Hereditary Parkinsonism-Associated Genetic Variations in PARK9 Locus Lead to Functional Impairment of ATPase Type 13A2
Current Protein & Peptide Science